IPO - LTR Pharma Ltd - 11 December 2023 #, page-3

Told to manage expectations….

The Prospectus can be accessed at - https://www.ltrpharma.automicipo.com.au/

Bids are due 9am AEST (Wednesday) – 15/11/2023.

Please manage expectations as allocation will be very hard to get.

Please let us know if you are interested.



LTR Pharma is looking to disrupt the blockbuster ED market, by commercialising a ‘First in Class’ intra-nasal drug (PDE5) delivery platform called SDS089-PK01 (SPONTAN). In simple terms, their intellectual property is in the ability to convert the active ingredient in the ED pill, to a fast-onset nasal spray.

Notes

ED is a global blockbuster market.

• Spontan Up to 6 times faster when compared to oral delivery (pills) (peak onset 10mins)
• Repurposing a now generic PDE5 drug – by changing the delivery method
• Less active ingredient offers fewer potential side effects.
• Faster onset can solve the reason up to 50% of patients discontinue using oral ED drugs in the first year.
• Fast pathway to market. (there are no phase 1, 2 or 3 trials)
• No extensive and expensive trials. Bioequivalence trial to commence in February 2024 (in Sydney).
• Mkt Cap $27.8m, EV$20.2m

• Key details below
• Term Sheet
• Presentation
• Prospective investors can view the Prospectus at - https://www.ltrpharma.automicipo.com.au/

LTD (“LTR”, “LTR PHARMA” OR PROPOSED ASX TICKER CODE “ASX:LTP” INITIAL PUBLIC OFFERING TO RAISE A MINIMUM OF A$6.0M

LTR Pharma Limited (LTP) is an Australian clinical-stage biopharmaceutical company. LTP has developed and is in the process of commercialising a ‘First in Class’ intra-nasal drug (PDE5) delivery platform called SDS089-PK01 (SPONTAN) to treat patients with ED. SPONTAN is targeted to meet a range of specific unmet clinical and patient needs, allowing rapid onset of action and reduced side effects from lower a lower dosage formulation, compared to other similar products. SPONTAN has successfully completed Phase 1 Human Proof of Concept in California and is undergoing an expedited regulatory pathway with the TGA and FDA, through a change of administration for an already approved drug vardenafil.

IPO round to raise a minimum of A$6.0m:

• Issue of ~30.0m fully paid ordinary shares in LTR Pharma Limited
• Issue price of $0.20
• Ability to accept oversubscription of a further $1.0m, comprising an issue of ~5.0m additional new shares under the Offer

The Prospectus has now cleared the ASIC exposure period and the offer is open.

For further information please see this video -